Skip to main content
OpenTrials
Completed

NCT Number: NCT04387994

Determination of Circulating Placental Biomarkers Levels to Predict the Pregnancy Outcome of First Trimester After IVF.

This study will assess the predictive potential of circulating placental biomarkers for spontaneous miscarriage within the following month in an IVF setting. It is hypothesized that a robust algorithm including one or more of these biomarkers may allow for the accurate same-day distinction between women with a low and high risk of a spontaneous miscarriage.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–48 year

Sex eligibility

Female

Study type

Observational

Primary location

Instituto Valenciano de Infertilidade de Lisboa

Lisbon, 1800-282, Portugal

About this study

Spontaneous miscarriage is the most common adverse outcome in the first trimester of pregnancy. This is a particularly stressful situation for the expecting parents, since their need for a final diagnosis is frustrated for a potentially extended period on time which may span over several weeks. The emotional impact of this complication can be devastating, resulting frequently in depression and anxiety which may last for several months.

In an attempt to allow for an earlier and more accurate diagnosis of first trimester miscarriage, multiple circulating placental biomarkers have been tested over last years. However, their potential usefulness in an everyday clinical setting remains unclear.

The investigators propose a single-center observational prospective cohort study in an in vitro fertilization (IVF) setting. All recruited consenting patients will collect blood samples on a day of the first pregnancy test (12-14 days after embryo transfer) and at the time of the first (at 5 weeks plus 4-5 days of gestational age) and second (at 7 weeks plus 4-5 days of gestational age) ultrasound scan to determine the circulating placental biomarkers concentrations in order to predict the pregnancy outcome (spontaneous miscarriage versus evolutive pregnancy) until the first obstetrical ultrasound, performed between 11 weeks and 13 weeks plus 6 days of gestational age.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: ≥18 and <49 years old
  • Body Mass Index (BMI): ≥18.5 Kg/m2 and <30 Kg/m2
  • Pregnancy resulting from Assisted Reproductive Technologies (ART)
  • Single blastocyst transfer pregnancy
  • Pregnancy confirmed by blood test
  • Gestational age < 6 weeks at the first US
  • Signed and dated informed consent

Exclusion criteria

  • Spontaneous pregnancies
  • Treatment for prevention of miscarriage (i.e. corticoids, aspirin, heparin)
  • Those unable to provide the 11th-13th week ultrasound report
  • Those unable to comprehend the investigational nature of the proposed study

Treatment and study plan

Blood samples collection

Other

Collection of blood samples from consenting subjects to evaluate circulating biomarkers concentrations.

Primary outcomes

  1. Pregnancy outcome (spontaneous miscarriage versus evolutive pregnancy) at the first trimester ultrasound

    Time frame: Up to the first trimester ultrasound (11 to 13 weeks plus 6 days of gestation)

    Measurement of circulating placental biomarkers levels

Secondary outcomes

  1. Abnormal outcomes of early pregnancy (biochemical pregnancy and extra uterine pregnancy)

    Time frame: Up to the first trimester ultrasound (11 to 13 weeks plus 6 days of gestation)

    Measurement of circulating placental biomarkers levels

  2. Risk of obstetric complications/adverse outcomes for first-trimester spontaneous miscarriage

    Time frame: Up to the first trimester ultrasound (11 to 13 weeks plus 6 days of gestation)

    Measurement of circulating placental biomarkers levels

Sponsors and collaborators

Lead sponsor

Instituto Valenciano de Infertilidade de Lisboa

Network

Collaborators

  • Roche Pharma AG

Registry information

Official study title

Early Prediction of First Trimester Miscarriage After IVF With Serum Circulating Placental Biomarkers: a Pilot Study to Develop a Prediction Model.

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
May 14, 2020
Registry last updated
Aug 4, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.